mutations presented the fact that, as discussed below, CLL therapy relies on the presence or absence of those mutations. The current consensus is the fact, apart from clonal mutations, subclonal mutations having a variant allelic frequency ranging from five to 10% (and as a consequence under the threshold of detection by typical molecular methods)